Phase II clinical trial design: Methods in translational research from the genitourinary committee at the Eastern Cooperative Oncology Group

Clinical Cancer Research

Volumn 12, Issue 7 I, 2006, Pages 1966-1969

  Gray, Robert ^a   Manola, Judith ^b   Saxman, Scott ^d   Wright, John ^d   Dutcher, Jan ^e   Atkins, Michael ^c   Carducci, Michael ^f   See, William ^h   Sweeney, Christopher ⁱ   Liu, Glenn ^j   Stein, Mark ^g   Dreicer, Robert ^k   Wilding, George ^j   DiPaola, Robert S ^g  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Our Lady of Mercy Cancer Center   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ INDIANA UNIVERSITY   (United States)

^j UNIVERSITY OF WISCONSIN   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYTOSTATIC AGENT; PLACEBO;

CANCER GROWTH; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; MEDICAL SOCIETY; METHODOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ADVISORY COMMITTEES; CLINICAL TRIALS, PHASE II; HUMANS; MODELS, STATISTICAL; NEOPLASMS; PROFESSIONAL STAFF COMMITTEES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 33646239403     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1136     Document Type: Review

References (13)

1. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
2. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001;19:265-72.
3. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-81.
4. Simon RM, Steinberg SM, Hamilton M, et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001;19:1848-54.
5. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002;20:4478-84.
6. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
7. Scher HI, Heller G. Picking the winners in a sea of plenty. Clin Cancer Res 2002;8:400-4.
8. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54.
9. Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Exper Opin Biol Ther 2005;5:1085-93.
10. Temple RJ. Enrichment designs: efficiency in development of cancer treatments. J Clin Oncol 2005;23:4838-9.
11. Freidlin B, Simon R. Evaluation of randomized discontinuation design. J Clin Oncol 2005;23:5094-8.
12. Stadler WM, Rosner G, Small E, et al. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative anti-angiogenic agent carboxyaminoimidazole in renal cell carcinoma-CALGB 69901. J Clin Oncol 2005;23:3726-32.
13. Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat Med 1998;17:1563-80.